As an anti-inflammatory, theanine decreases proinflammatory factors, including cyclooxygenase-2, prostaglandin E2, nitric oxide synthase, and nitric oxide
Its core pathological feature is excessive accumulation of adipose tissue, accompanied by abnormal proliferation, differentiation, and metabolic dysfunction of adipocytes, which in turn induce a series of complications including insulin resistance, nonalcoholic fatty liver disease, and cardiovascular diseases
Growth hormonereleasing peptide 6 protection of hypothalamic neurons from glutamate excitotoxicity is caspase independent and not mediated by insulinlike growth factor I
Results confirmed liraglutide's superiority: HbA1c reduction: -1.48% (liraglutide) vs -1.28% (exenatide ER) Weight loss: -3.57 kg (liraglutide) vs -2.68 kg (exenatide ER) Weight Loss Comparison# Exenatide (DURATION Program)# Exenatide was developed for type 2 diabetes, not weight management: DURATION-1: 3.7 kg weight loss with Bydureon over 30 weeks DURATION-5: 2.3 kg weight loss over 24 weeks Three-year extension: 2.3 kg sustained weight reduction No FDA approval for chronic weight management Liraglutide (SCALE Program)# Liraglutide was specifically developed for obesity at the higher 3.0 mg dose: SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015): 8.0% mean weight loss at 56 weeks 63.2% achieved 5% or more weight loss
2017), the real value of curcumin in Alzheimers therapy remains unclear
Without a strategy, GLP-1s could become a driver of runaway pharmacy costs in employer-sponsored health plans
